Why Tempus AI’s Lens upgrade matters for precision oncology drug development
Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.
Medical Devices & Diagnostics
Pharma & Biotech
How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
Pharma has too much data and too little time. AstraZeneca’s Owkin deal tests whether agentic AI can sharpen drug development decisions.
Pharma & Biotech
Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery
Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of
Pharma & Biotech
Can Lynx Analytics’ Lumen framework reshape AI-driven decision-making in life sciences?
Lynx Analytics has introduced Lumen, a dedicated agentic artificial intelligence framework designed to support complex decision-making across life sciences workflows. The launch was anchored by a real-world deployment at AstraZeneca, where a custom-built application called IlluminAI is now embedded in the oncology team’s brand planning process across international markets. The framework is positioned as a
Pharma & Biotech
How eClinical Solutions is embedding agentic AI into trial data workflows for 2026
eClinical Solutions LLC has officially launched its elluminate AI agents, embedding agentic automation into its elluminate Clinical Data Cloud ecosystem. First previewed at the company’s ENGAGE conference in October 2025, these AI agents will become available in early 2026 and are designed to assist in four critical clinical trial workflows: data mapping, data review, risk-based